Disease Spotlight
Agitation in Alzheimer's Dementia

Test Your Knowledge

Did you know?

Peer to Peer Insights
Profile Image
  • Add Media
  • Saved

10mo
Environmental risk factors for all-cause dementia, Alzheimer's disease dementia, vascular dementia, and mild cognitive impairment: An umbrella review and meta-analysis - PubMed

Environmental risk factors for all-cause dementia, Alzheimer's disease dementia, vascular dementia, and mild cognitive impairment: An umbrella review and meta-analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39889875/

Achieving stronger air quality targets has the potential to reduce population-level dementia risk. Neighbourhood (i.e., greenness and chronic noise) and occupational (i.e., shift work) characteristics are associated with dementia and...

Environmental exposures like air pollutants, noise, and shift work increase dementia risk, while greenness is protective. Stronger air quality policies could help reduce population-level dementia incidence.

  • Saved

11mo
Clinical Aspects of Mental Imagery in Alzheimer's Disease-Related Dementia: A Review of Cognitive, Motor, and Emotional Interventions - PubMed

Clinical Aspects of Mental Imagery in Alzheimer's Disease-Related Dementia: A Review of Cognitive, Motor, and Emotional Interventions - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40149745/

The present review describes the use and effectiveness of mental imagery in Alzheimer's disease-related dementia. Six databases were thoroughly searched from January 2010 to December 2024. Different types of studies...

https://pubmed.ncbi.nlm.nih.gov/40149745/

Mental imagery shows promise in enhancing motor, cognitive, and emotional well-being in Alzheimer’s-related dementia, but further studies with larger, more uniform samples and improved tools are needed.

  • Saved

11mo
Intelligent Robot Interventions for People With Dementia: Systematic Review and Meta-Analysis of Randomized Controlled Trials - PubMed

Intelligent Robot Interventions for People With Dementia: Systematic Review and Meta-Analysis of Randomized Controlled Trials - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40063933/

PROSPERO CRD42024523007; https://tinyurl.com/mwscn985.

Intelligent robots significantly reduce agitation and anxiety in dementia patients, though effects on cognition, depression, or quality of life are limited; longer interventions yield better outcomes regardless of robot type.

  • Saved

11mo
Investigating neuropathological correlates of hyperactive and psychotic symptoms in dementia: a systematic review - PubMed

Investigating neuropathological correlates of hyperactive and psychotic symptoms in dementia: a systematic review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39949536/

INPLASY2024100082.

This systematic review links HIDA and psychosis symptoms in dementia to overlapping neural circuit disruptions, especially in the amygdala, with TAUopathy and mixed proteinopathies being central contributors over beta-amyloid.

  • Saved

1yr
Brexpiprazole for Agitation Associated With Dementia Due to Alzheimer's Disease - PubMed

Brexpiprazole for Agitation Associated With Dementia Due to Alzheimer's Disease - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39053890/

Alzheimer's disease (AD) is a prevalent neurodegenerative disease characterized by progressive cognitive and functional decline. Nearly all patients with AD develop neuropsychiatric symptoms (NPSs). Agitation is one of the most...

Brexpiprazole for Agitation Associated With Dementia Due to Alzheimer's Disease

Key Points

  • Source: Journal of the Post-Acute and Long-Term Care Medical Association
  • Conclusions/Relevance: Agitation associated with Alzheimer's disease (AAD) is a distressing neuropsychiatric symptom for both patients and their care partners. It may also be linked to faster disease progression and increased mortality.
  • This article discusses an FDA-approved medication for AAD and reviews the pharmacology, clinical trial data, and implications for long-term care settings. This oral atypical antipsychotic acts as a partial agonist at serotonin 5-HT1A and dopamine D2 and D3 receptors, and as an antagonist at serotonin 5-HT2A, 5-HT2B, 5-HT7, and noradrenergic α1A, α1B, α1D, and α2C receptors.
  • The article also highlights the potential for other upcoming agents in the treatment of agitation associated with AD.